Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia [Yahoo! Finance]
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.